ClinicalTrials.gov lists 33 studies of retatrutide (LY3437943). Of the 14 Phase 3 trials, 5 are marked completed, and across all studies only 2 have posted results to the registry. So far one Phase 3 trial has a peer-reviewed results paper; the rest of the Phase 3 evidence is sponsor topline announcements. This page tracks what exists, where it is published and how far it has been reviewed. It does not restate trial outcomes.
At a glance
| Phase | Total | Completed | Ongoing |
|---|---|---|---|
| Phase 3 | 14 | 5 | 9 |
| Phase 2 | 4 | 3 | 1 |
| Phase 1 | 14 | 13 | 1 |
| Expanded access | 1 | 0 | 1 |
Registered studies
Every study returned by a ClinicalTrials.gov intervention search for retatrutide, newest first within each phase. Status, enrolment and dates are exactly as the sponsor has reported them to the registry.
Phase 3 (14)
TRIUMPH-9
Active, not recruitingA Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
- Registry ID
- NCT07357415
- Condition
- Obesity, Overweight
- Enrolment
- 600 (planned)
- Dates
- Started Jan 2026 · primary completion Oct 2028 (est.)
- Results on registry
- Not posted
- Registry updated
- Jun 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
TRIUMPH-8
Active, not recruitingA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
- Registry ID
- NCT07232719
- Condition
- Obesity, Overweight
- Enrolment
- 250 (planned)
- Dates
- Started Nov 2025 · primary completion Jul 2027 (est.)
- Results on registry
- Not posted
- Registry updated
- Apr 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT07165028
RecruitingA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Registry ID
- NCT07165028
- Condition
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Enrolment
- 4,500 (planned)
- Dates
- Started Oct 2025 · primary completion Aug 2030 (est.)
- Results on registry
- Not posted
- Registry updated
- Sep 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
TRIUMPH-7
Active, not recruitingA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
- Registry ID
- NCT07035093
- Condition
- Obesity, Overweight, Chronic Low Back Pain (CLBP)
- Enrolment
- 586 (planned)
- Dates
- Started May 2025 · primary completion Sep 2027 (est.)
- Results on registry
- Not posted
- Registry updated
- Sep 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
TRIUMPH-6
Active, not recruitingA Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
- Registry ID
- NCT06859268
- Condition
- Obesity
- Enrolment
- 643 (planned)
- Dates
- Started Mar 2025 · primary completion Apr 2028 (est.)
- Results on registry
- Not posted
- Registry updated
- Mar 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
TRIUMPH-5
Active, not recruitingA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
- Registry ID
- NCT06662383
- Condition
- Obesity
- Enrolment
- 800 (planned)
- Dates
- Started Nov 2024 · primary completion Nov 2026 (est.)
- Results on registry
- Not posted
- Registry updated
- Jul 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT06383390
Active, not recruitingThe Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Registry ID
- NCT06383390
- Condition
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Enrolment
- 10,000 (planned)
- Dates
- Started Apr 2024 · primary completion Feb 2029 (est.)
- Results on registry
- Not posted
- Registry updated
- Sep 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
TRANSCEND-T2D-1
CompletedEffect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
- Registry ID
- NCT06354660
- Condition
- Diabetes Type 2
- Enrolment
- 537 (actual)
- Dates
- Started Apr 2024 · primary completion Jan 2026
- Results on registry
- Not posted
- Registry updated
- Mar 2026
Published evidence
- Bajaj et al. The Lancet 2026 — primary trial report, peer-reviewed
- Sponsor announcement, 6 June 2026 — not peer-reviewed
- Sponsor announcement, 19 March 2026 — not peer-reviewed
Trial name from Bajaj et al., Lancet 2026; the registry record has no acronym.
NCT06297603
Active, not recruitingEffect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- Registry ID
- NCT06297603
- Condition
- Type 2 Diabetes
- Enrolment
- 320 (planned)
- Dates
- Started Mar 2024 · primary completion Oct 2026 (est.)
- Results on registry
- Not posted
- Registry updated
- Jul 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT06260722
Active, not recruitingEffect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- Registry ID
- NCT06260722
- Condition
- Diabetes Mellitus, Type 2
- Enrolment
- 1,250 (planned)
- Dates
- Started Feb 2024 · primary completion Aug 2026 (est.)
- Results on registry
- Not posted
- Registry updated
- Apr 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
TRIUMPH-4
CompletedA Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
- Registry ID
- NCT05931367
- Condition
- Obesity, Overweight, Osteo Arthritis Knee
- Enrolment
- 445 (actual)
- Dates
- Started Aug 2023 · primary completion Nov 2025
- Results on registry
- Not posted
- Registry updated
- Jan 2026
Published evidence
- Giblin et al. Diabetes, Obesity and Metabolism 2026 — design and rationale, peer-reviewed
- Sponsor announcement, 11 December 2025 — not peer-reviewed
TRIUMPH-2
CompletedA Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
- Registry ID
- NCT05929079
- Condition
- Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
- Enrolment
- 1,152 (actual)
- Dates
- Started Jul 2023 · primary completion Jun 2026
- Results on registry
- Not posted
- Registry updated
- Jul 2026
Published evidence
- Giblin et al. Diabetes, Obesity and Metabolism 2026 — design and rationale, peer-reviewed
- Sponsor announcement, 23 July 2026 — not peer-reviewed
TRIUMPH-1
CompletedA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
- Registry ID
- NCT05929066
- Condition
- Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
- Enrolment
- 2,335 (actual)
- Dates
- Started Jul 2023 · primary completion Apr 2026
- Results on registry
- Not posted
- Registry updated
- Aug 2026
Published evidence
- Giblin et al. Diabetes, Obesity and Metabolism 2026 — design and rationale, peer-reviewed
- Sponsor announcement, 6 June 2026 — not peer-reviewed
- Sponsor announcement, 21 May 2026 — not peer-reviewed
TRIUMPH-3
CompletedA Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
- Registry ID
- NCT05882045
- Condition
- Obesity, Cardiovascular Diseases
- Enrolment
- 1,946 (actual)
- Dates
- Started May 2023 · primary completion Apr 2026
- Results on registry
- Not posted
- Registry updated
- Jul 2026
Published evidence
- Giblin et al. Diabetes, Obesity and Metabolism 2026 — design and rationale, peer-reviewed
- Sponsor announcement, 23 July 2026 — not peer-reviewed
Phase 2 (4)
GZBF
RecruitingEffect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
- Registry ID
- NCT07467447
- Condition
- Obesity
- Enrolment
- 300 (planned)
- Dates
- Started Feb 2026 · primary completion Mar 2027 (est.)
- Results on registry
- Not posted
- Registry updated
- Mar 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
TRANSCEND-CKD
CompletedA Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Registry ID
- NCT05936151
- Condition
- Overweight or Obesity, CKD, Type 2 Diabetes
- Enrolment
- 146 (actual)
- Dates
- Started Jul 2023 · primary completion Oct 2025
- Results on registry
- Not posted
- Registry updated
- Nov 2025
Published evidence
- Heerspink et al. Nephrology Dialysis Transplantation 2026 — design and rationale, peer-reviewed
Trial name from Heerspink et al., Nephrol Dial Transplant 2026; the registry record has no acronym.
NCT04881760
CompletedA Study of LY3437943 in Participants Who Have Obesity or Are Overweight
- Registry ID
- NCT04881760
- Condition
- Obesity, Overweight
- Enrolment
- 338 (actual)
- Dates
- Started May 2021 · primary completion May 2022
- Results on registry
- Posted
- Registry updated
- Sep 2023
Published evidence
- Sanyal et al. Nature Medicine 2024 — pre-specified substudy, peer-reviewed
- Jastreboff et al. New England Journal of Medicine 2023 — primary trial report, peer-reviewed
NCT04867785
CompletedA Study of LY3437943 in Participants With Type 2 Diabetes
- Registry ID
- NCT04867785
- Condition
- Type 2 Diabetes
- Enrolment
- 281 (actual)
- Dates
- Started May 2021 · primary completion Jul 2022
- Results on registry
- Posted
- Registry updated
- Jul 2023
Published evidence
- Coskun et al. The Lancet Diabetes & Endocrinology 2025 — pre-specified substudy, peer-reviewed
- Rosenstock et al. The Lancet 2023 — primary trial report, peer-reviewed
Phase 1 (14)Show
NCT06982846
CompletedA Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
- Registry ID
- NCT06982846
- Condition
- Type 2 Diabetes Mellitus
- Enrolment
- 80 (actual)
- Dates
- Started Jun 2025 · primary completion May 2026
- Results on registry
- Not posted
- Registry updated
- Jun 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT06982859
Active, not recruitingA Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- Registry ID
- NCT06982859
- Condition
- Diabetes Mellitus, Insulin Sensitivity
- Enrolment
- 95 (planned)
- Dates
- Started Jun 2025 · primary completion Dec 2026 (est.)
- Results on registry
- Not posted
- Registry updated
- Jul 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT06808802
CompletedTo Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
- Registry ID
- NCT06808802
- Condition
- Healthy
- Enrolment
- 30 (actual)
- Dates
- Started Feb 2025 · primary completion Apr 2025
- Results on registry
- Not posted
- Registry updated
- Jun 2025
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT06313528
CompletedA Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
- Registry ID
- NCT06313528
- Condition
- Obesity
- Enrolment
- 85 (actual)
- Dates
- Started Mar 2024 · primary completion Aug 2025
- Results on registry
- Not posted
- Registry updated
- Sep 2025
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT06039826
CompletedA Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- Registry ID
- NCT06039826
- Condition
- Overweight
- Enrolment
- 46 (actual)
- Dates
- Started Sep 2023 · primary completion Jul 2024
- Results on registry
- Not posted
- Registry updated
- Jul 2024
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT06003465
CompletedA Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
- Registry ID
- NCT06003465
- Condition
- Healthy
- Enrolment
- 57 (actual)
- Dates
- Started Aug 2023 · primary completion Feb 2024
- Results on registry
- Not posted
- Registry updated
- Mar 2024
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT05959096
CompletedA Study of LY3437943 in Healthy Participants With a High Body Mass Index
- Registry ID
- NCT05959096
- Condition
- Healthy
- Enrolment
- 85 (actual)
- Dates
- Started Jul 2023 · primary completion Jul 2024
- Results on registry
- Not posted
- Registry updated
- Oct 2024
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT05916560
CompletedA Study of LY3437943 in Participants With Impaired and Normal Liver Function
- Registry ID
- NCT05916560
- Condition
- Healthy, Hepatic Insufficiency
- Enrolment
- 43 (actual)
- Dates
- Started Jul 2023 · primary completion Mar 2025
- Results on registry
- Not posted
- Registry updated
- Apr 2025
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT05611957
CompletedA Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
- Registry ID
- NCT05611957
- Condition
- Healthy, Renal Insufficiency
- Enrolment
- 29 (actual)
- Dates
- Started Nov 2022 · primary completion Sep 2023
- Results on registry
- Not posted
- Registry updated
- Oct 2023
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT05548231
CompletedA Study of LY3437943 in Chinese Participants With Obesity Or Overweight
- Registry ID
- NCT05548231
- Condition
- Overweight, Obesity
- Enrolment
- 32 (actual)
- Dates
- Started Oct 2022 · primary completion Jul 2023
- Results on registry
- Not posted
- Registry updated
- Aug 2023
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT05445232
CompletedA Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- Registry ID
- NCT05445232
- Condition
- Obesity
- Enrolment
- 32 (actual)
- Dates
- Started Jul 2022 · primary completion Feb 2023
- Results on registry
- Not posted
- Registry updated
- Apr 2023
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT04823208
CompletedA Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
- Registry ID
- NCT04823208
- Condition
- Diabetes Mellitus, Type 2
- Enrolment
- 64 (actual)
- Dates
- Started May 2021 · primary completion Jun 2022
- Results on registry
- Not posted
- Registry updated
- Aug 2022
Published evidence
No peer-reviewed paper or sponsor announcement identified.
NCT04143802
CompletedA Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
- Registry ID
- NCT04143802
- Condition
- Diabetes Mellitus, Type 2
- Enrolment
- 72 (actual)
- Dates
- Started Dec 2019 · primary completion Dec 2020
- Results on registry
- Not posted
- Registry updated
- Jan 2021
Published evidence
- Urva et al. The Lancet 2022 — primary trial report, peer-reviewed
NCT03841630
CompletedA Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
- Registry ID
- NCT03841630
- Condition
- Healthy
- Enrolment
- 45 (actual)
- Dates
- Started Mar 2019 · primary completion Jul 2019
- Results on registry
- Not posted
- Registry updated
- Aug 2019
Published evidence
No peer-reviewed paper or sponsor announcement identified.
Expanded access (1)Show
NCT07629401
Available (expanded access)Pre-approval Expanded Access of Retatrutide (LY3437943)
- Registry ID
- NCT07629401
- Condition
- Obesity, Obesity-related Complications
- Enrolment
- —
- Dates
- No start date
- Results on registry
- Not posted
- Registry updated
- Aug 2026
Published evidence
No peer-reviewed paper or sponsor announcement identified.
Peer-reviewed publications
Primary trial reports, pre-specified substudies and design papers, matched to their registry IDs. Post-hoc analyses and questionnaire-development papers are not listed one by one; the PubMed search for retatrutide finds them.
Primary trial report · 2026
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj et al. The Lancet, 2026.
DOI 10.1016/S0140-6736(26)00967-0PubMed 42250575TRANSCEND-T2D-1
Design and rationale · 2026
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Giblin et al. Diabetes, Obesity and Metabolism, 2026.
DOI 10.1111/dom.70209PubMed 41090431TRIUMPH-1TRIUMPH-2TRIUMPH-3TRIUMPH-4
Matched by trial name (TRIUMPH-1 to -4); the PubMed record lists no registry IDs.
Design and rationale · 2026
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
Heerspink et al. Nephrology Dialysis Transplantation, 2026.
Pre-specified substudy · 2025
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Coskun et al. The Lancet Diabetes & Endocrinology, 2025.
Pre-specified substudy · 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Sanyal et al. Nature Medicine, 2024.
Primary trial report · 2023
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
Jastreboff et al. New England Journal of Medicine, 2023.
Primary trial report · 2023
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock et al. The Lancet, 2023.
Primary trial report · 2022
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva et al. The Lancet, 2022.
Discovery + Phase 1 · 2022
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
Coskun et al. Cell Metabolism, 2022.
DOI 10.1016/j.cmet.2022.07.013PubMed 35985340
Reports a Phase 1 single-ascending-dose study; the PubMed record does not state its registry ID.
Sponsor announcements
Eli Lilly has announced topline Phase 3 results by press release ahead of peer review. They are listed so the record is complete, but a press release is not a peer-reviewed paper. It reports the sponsor’s chosen headline analyses, and full methods and safety data follow later. Their figures are deliberately not reproduced here.
Topline results from TRIUMPH-2 and TRIUMPH-3
Also states a planned US Biologics License Application in Q1 2027. NCT05929079, NCT05882045
Additional Phase 3 results presented at the American Diabetes Association Scientific Sessions
Conference presentation; TRANSCEND-T2D-1 was published in The Lancet (listed above). NCT05929066, NCT06354660
Topline results from TRIUMPH-1
Topline only. NCT05929066
Topline results from TRANSCEND-T2D-1
Since superseded by the peer-reviewed Lancet paper. NCT06354660
Topline results from TRIUMPH-4
Topline only. NCT05931367
Limitations of this tracker
- The registry is sponsor-reported.Status and dates change when the sponsor updates the record, which can lag the real state of a trial by months. The “registry updated” date on each study shows how fresh its record is.
- Enrolment figures are planned until a study completes. Numbers marked “planned” are targets, and even “actual” figures can differ slightly from the number randomised in a later paper.
- One registry only. Studies registered solely elsewhere (for example the EU Clinical Trials Information System) and non-sponsor investigator studies without a ClinicalTrials.gov record will not appear.
- Topline is not the full result. Where a trial has only a sponsor announcement, the evidence has not been peer-reviewed and full safety data are not yet public.
- A registered trial is not an approval. Retatrutide is not approved as a medicine by the MHRA, the FDA or any other regulator. The sponsor has said it plans a US application in 2027.
How this page is maintained
The study list is regenerated from the ClinicalTrials.gov search for retatrutide (ClinicalTrials.gov API v2, query.intr=retatrutide). Papers are matched to registry IDs from their PubMed records, and sponsor announcements are checked against Eli Lilly’s releases. The registry was last checked on . Its data last changed on , and the publication and announcement lists were last reviewed on . Spotted a missing study or paper? Tell us through the contact details in the footer.